Announced
Financials
Tags
Cross Border
Majority
Private
Pending
Single Bidder
biotechnology research
Switzerland
Biotechnology
Acquisition
Friendly
Synopsis
Boehringer Ingelheim, an animal health care services provider, agreed to acquire T3 Pharmaceuticals, a clinical stage biotech company, for $509m. “The acquisition of T3 Pharma will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programs. This will bring us closer to achieving our vision of driving a paradigm shift in cancer care treatments,” Michel Pairet, Boehringer Ingelheim Member of the Board of Managing Directors.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.